Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06132880
Other study ID # KLK-S024
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 14, 2023
Est. completion date December 31, 2026

Study information

Verified date November 2023
Source Beijing Tsinghua Chang Gung Hospital
Contact Xiaowei Song
Phone 18810363866
Email sxwa01271@btch.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary purpose of this trial is to evaluate the effects of Human Urinary Kallidinogenase on improvement of neurological outcome, and early cerebral perfusion in acute ischemic stroke.


Description:

This is a multicentre, randomized, open label, blinded-endpoint trial that aims to investigate the effects of Human Urinary Kallidinogenase treatment on neurological outcomes, early cerebral perfusion in patients with acute anterior circulation ischemic stroke. Patients in intervention group will be given 0.15 peptide nucleic acids (PNA) Human Urinary Kallidinogenase concentrated solution for intravenous injection once a day for 10 days continuously, and those in the control group will be given conventional therapy. Both groups of patients will be on standard stroke care. In this study, patients who were eligible to the inclusion criteria and ineligible to the exclusion criteria will be randomly assigned into two groups by a 1:1 ratio after the informed consent form (ICF) was received. The total sample size will be 540. All patients will be followed up for 90 days. The primary outcome is the proportion of modified Rankin Scale 0-2. Besides, the investigators aimed to use computed tomography perfusion (CTP) evaluate the differences of ischemic penumbra volume and regional cerebral blood flow (rCBF) before and after treatment between intervention group and control group. Furthermore, this study adopts adaptive design, prospectively stating interim analyses with specified stopping rules, which allow for the possibility of the study to terminate early based on either determination of study success or of the futility to continue further enrollment.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 540
Est. completion date December 31, 2026
Est. primary completion date August 28, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. 18 to 80 years of age; 2. Diagnosis of anterior circulation acute ischemic stroke; 3. Within 48 hours of symptoms onset; 4. modified Rankin Scale (mRS) score=1 before this event; 5. 5=NIHSS=20 at screening; 6. The availability of informed consent. Exclusion Criteria: 1. Patients who have already or are going to receive intravenous thrombolytic/mechanical thrombectomy therapy after onset; 2. Patients with severe consciousness disorder, NIHSS 1a consciousness level score=2; 3. Patients with limited limb mobility such as fractures and claudication upon admission; 4. Patients who have already or are going to receive Edaravone injection, Edaravone and DeKanol concentrated solution for injection, Butylphthalide and sodium chloride injection or Butylphthalide soft capsules after onset; 5. Hypotensive (systolic blood pressure <90 mmHg or diastolic blood pressure<60 mmHg) on admission; 6. History of severe drug or food allergy, allergy or intolerance to Human Urinary Kallidinogenase; 7. Patients who have been on angiotensin-converting enzyme inhibitor (ACEI) drugs and within 5 half-lives (according to the specific drug instructions) before initiate Human Urinary Kallidinogenase treatment; 8. Pregnancy, lactation, or planned pregnancy within 90 days; 9. Patients with severe renal failure or impairment (eGFR<30ml/min/1.73m2) at screening; 10. Severe hepatic dysfunction, elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (more than 2.5 times of upper limit of normal value), other liver diseases such as acute and chronic hepatitis, cirrhosis, etc; 11. Patients with heart failure (NYHA class III or IV), unstable angina pectoris, acute myocardial infarction, severe arrhythmia, and degree II and III cardiac conduction obstruction within 6 months prior to randomization; 12. Heavy drinking in the three months before screening, drinking=5 standard drinks per day (1 standard drink is equivalent to120ml wine, 360ml beer or 45ml liquor); 13. Drug Abuse or addiction in the past year; 14. Patients with a malignant tumor, severe systemic diseases, or estimated survival time <90 days; 15. Patients with severe mental disorders or dementia unable to complete the informed consent and follow-up; 16. Have participated in another interventional clinical study within 30 days before randomization or are participating in another interventional clinical study; 17. Other cases unsuitable for this clinical study assessed by researcher.

Study Design


Intervention

Drug:
Human Urinary Kallidinogenase
Intravenous injections of urinary kallidinogenase (0.15 peptide nucleic acids (PNA) in 0.9% NaCl) intravenous drip QD for 10 days.
Other:
Clinical Routine Treatment
Conventional therapy of acute ischemic stroke after based on Chinese guidelines

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Beijing Tsinghua Chang Gung Hospital Peking University People's Hospital

Outcome

Type Measure Description Time frame Safety issue
Other Change of regional cerebral blood volume (rCBV) in Tmax>6s area Change of regional cerebral blood volume (rCBV) in Tmax>6s area on CTP from baseline to 5 days after treatment 5 days
Other Change of mean transit time (MTT) in Tmax>6s area Change of mean transit time (MTT) in Tmax>6s area on CTP from baseline to 5 days after treatment 5 days
Other Change of Tmax>4s volume Change of Tmax>4s volume on CTP from baseline to 5 days after treatment 5 days
Other Change of Tmax>8s volume Change of Tmax>8s volume on CTP from baseline to 5 days after treatment 5 days
Other Change of Tmax>10s volume Change of Tmax>10s volume on CTP from baseline to 5 days after treatment 5 days
Other Change of National Institute of Health stroke scale (NIHSS) score at day 3 after treatment. Change of National Institute of Health stroke scale (NIHSS) score from baseline to 3 days after treatment. NIHSS ranges from 0 to 42, a low value represents a better outcome. 3 days
Other Stroke recurrence rate Stroke recurrence rate within 90 days 90 days
Other Infarct core volume Infarct core volume at 5 days after treatment on diffusion weighted imaging (DWI) 5 days
Other Mini-Mental State Examination (MMSE) at day 90. Mini-mental State Examination(MMSE)at day 90. The MMSE uses a 0-30 score scale which effected by age and education experience. Cognitive impairment is diagnosed when MMSE =17 for illiteracy,MMSE =20 for those who take less than 6-years primary education,MMSE =24 for those have at least a middle school education. 90 days
Other Montreal Cognitive Assessment (MoCA) at day 90. Montreal Cognitive Assessment (MoCA) at day 90. The MoCA uses a 0-30 score scale and defines impairment as follows: score of 18-25=mild,10-17=moderate and <10 =severe. 90 days
Primary The proportion of patients with modified Rankin Scale (mRS) 0-2 at day 90 The proportion of patients with modified Rankin Scale (mRS) 0-2 at day 90. mRS scores range from 0 to 6. 0=no symptoms,1 = symptoms without clinically significant disability,2 = slight disability,3 = moderate disability,4 = moderately severe disability,5 = severe disability; and 6 = death. 90 days
Secondary Change of Tmax>6s volume Change of Tmax>6s volume on CTP from baseline to 5 days after treatment 5 days
Secondary Change of rCBF in Tmax>6s area Change of rCBF in Tmax>6s area on CTP from baseline to 5 days after treatment 5 days
Secondary Ordinal distribution of modified Rankin Scale (mRS) at day 90 Ordinal distribution of modified Rankin Scale (mRS) at day 90. mRS scores range from 0 to 6. 0=no symptoms,1 = symptoms without clinically significant disability,2 = slight disability,3 = moderate disability,4 = moderately severe disability,5 = severe disability; and 6 = death. 90 days
Secondary The proportion of patients with modified Rankin Scale (mRS) 0-1 at day 90 The proportion of patients with modified Rankin Scale (mRS) 0-1 at day 90. mRS scores range from 0 to 6. 0=no symptoms,1 = symptoms without clinically significant disability,2 = slight disability,3 = moderate disability,4 = moderately severe disability,5 = severe disability; and 6 = death. 90 days
Secondary Change of National Institute of Health stroke Scale (NIHSS) score at day 5 after treatment. Change of National Institute of Health stroke Scale (NIHSS) score from baseline to 5 days after treatment. NIHSS ranges from 0 to 42, a low value represents a better outcome. 5 days
Secondary Change of National Institute of Health stroke scale (NIHSS) score at day 10 after treatment. Change of National Institute of Health stroke scale (NIHSS) score from baseline to 10 days after treatment. NIHSS ranges from 0 to 42, a low value represents a better outcome. 10 days
See also
  Status Clinical Trial Phase
Recruiting NCT06113848 - Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy Phase 3
Completed NCT04069546 - The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency N/A
Active, not recruiting NCT05700097 - Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy Phase 2
Recruiting NCT06058130 - Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis N/A
Recruiting NCT04415164 - Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke Phase 4
Recruiting NCT05363397 - Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke Phase 2
Completed NCT05429658 - Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System N/A
Recruiting NCT05390580 - Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct N/A
Enrolling by invitation NCT05515393 - A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke Phase 2
Active, not recruiting NCT05070260 - ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo Phase 2/Phase 3
Terminated NCT05547412 - Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
Completed NCT03366818 - New Stent Retriever, VERSI System for AIS N/A
Not yet recruiting NCT06437431 - Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy Phase 2/Phase 3
Not yet recruiting NCT06040476 - Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS) Phase 2
Not yet recruiting NCT05293080 - Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE Phase 3
Completed NCT02223273 - Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke) N/A
Completed NCT02586233 - Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke Phase 1/Phase 2
Not yet recruiting NCT01594190 - Physical Activity Immediately After Acute Cerebral Ischemia N/A
Terminated NCT01694381 - Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor Early Phase 1
Completed NCT01120301 - Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3) Phase 3